Skip to main content
Midas Edge

RIGEL PHARMACEUTICALS INC

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

RIGEL PHARMACEUTICALS, IN****C.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024

INDEX

​ · ​ · ​
​​​Page
PART IFINANCIAL INFORMATION​3
Item 1.Financial Statements​3
​Condensed Balance Sheets — June 30, 2024 (Unaudited) and December 31, 2023​3
​Condensed Statements of Operations (Unaudited) — three and six months ended June 30, 2024 and 2023​4
​Condensed Statements of Comprehensive Loss (Unaudited) — three and six months ended June 30, 2024 and 2023​5
​Condensed Statements of Stockholders’ Deficit (Unaudited) — three and six months ended June 30, 2024 and 2023​6
​Condensed Statements of Cash Flows (Unaudited) — six months ended June 30, 2024 and 2023​7
​Notes to Condensed Financial Statements (Unaudited)​8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations​24
Item 3.Quantitative and Qualitative Disclosures About Market Risk​45
Item 4.Controls and Procedures​45
PART IIOTHER INFORMATION​45
Item 1.Legal Proceedings​45
Item 1A.Risk Factors​46
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds​96
Item 3.Defaults Upon Senior Securities​96
Item 4.Mine Safety Disclosures​96
Item 5.Other Information​96
Item 6.Exhibits​97
​​​​
Signatures​98
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.